Clinical Trial

Barcelona Esquerra Glaucoma Artificial Intelligence-based Screening Program (BEGAS)

Study acronym: BEGAS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 9, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Two primary care-based screening systems will be tested to identify subjects with referrable glaucoma to hospital care. Subjects between 45 to 64 years old living in the metropolitan area of Barcelona will be invited to participate in a one-time visit, with an optic disc examination and intraocular pressure (IOP). The criteria for referring a patient will be the detection of glaucoma but with two different approaches depending on which Integrated Practice Unit (IPU) the patients will be allocated to: one arm using an Artificial Intelligence (AI) reading software of the optic disc picture; and the other one will base their referral after an ophthalmic examination performed by an ophthalmologist. In both circuits, an optic nerve head photography will be obtained, and a masked reading center will be established to determine the ground truth for diagnosis. This screening trial will explore the level of agreement between both systems and the cost-effectiveness of each of them. Secondary analyses will include potential diagnostic composite scores (including other ancillary tests, such as optical coherence tomography images, that could maximize the screening process); the identification of population and disease characteristics (type of glaucoma, intraocular pressure) that could increase the effectivity and adherence to the screening process.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-02.
Status change: Not Yet Recruiting → Recruiting 2024-10-08
Trial Details
NCT Number NCT06353542
Lead Sponsor Hospital Clinic of Barcelona
Conditions Glaucoma
Enrollment 500 participants
Start Date 2024-05-02
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2024-10-09